Back to Search
Start Over
Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia.
- Source :
-
Leukemia research [Leuk Res] 2009 Aug; Vol. 33 (8), pp. 1089-95. Date of Electronic Publication: 2009 Feb 04. - Publication Year :
- 2009
-
Abstract
- Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P=0.038) treatment free survival. Culture of CLL cells with solid phase CD83 mAb+IL-4 significantly increases sCD83 release (23-117-fold, P=0.013) and ligation of normal donor PBMC with solid phase CD83 mAb alone induces similar significant increases in sCD83 release (P=0.003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression.
- Subjects :
- Adolescent
Adult
Aged
Antibodies, Monoclonal immunology
Antibodies, Monoclonal pharmacology
Antigens, CD immunology
Chronic Disease
Disease-Free Survival
Female
Humans
Immunoglobulins immunology
Interleukin-4 immunology
Interleukin-4 pharmacology
Leukemia, Lymphoid drug therapy
Leukemia, Lymphoid immunology
Leukemia, Lymphoid mortality
Male
Membrane Glycoproteins immunology
Middle Aged
Neoplasm Proteins immunology
Predictive Value of Tests
RNA, Messenger blood
RNA, Messenger immunology
RNA, Neoplasm blood
RNA, Neoplasm immunology
Reverse Transcriptase Polymerase Chain Reaction methods
Survival Rate
Tumor Cells, Cultured
CD83 Antigen
Antigens, CD blood
Immunoglobulins blood
Leukemia, Lymphoid blood
Membrane Glycoproteins blood
Neoplasm Proteins blood
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5835
- Volume :
- 33
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Leukemia research
- Publication Type :
- Academic Journal
- Accession number :
- 19195701
- Full Text :
- https://doi.org/10.1016/j.leukres.2009.01.001